Skip to main content

01-04-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TATTON trial – Investigating savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

Related topics

More on this topic